The finding, in one line
Do the free stool test your health service mails you, and your risk of dying from bowel cancer looks a lot lower. A large Swedish study puts a number on it: 43% lower for people who actually took part.
That is the headline, and it holds up better than most screening headlines because of how the researchers handled the awkward part. More on that below.
| Finding | Plain-English meaning |
|---|---|
| Doing the stool test was tied to 43% lower bowel-cancer death risk | For people who actually completed the mailed test, deaths from bowel cancer were far lower. |
| Being invited was tied to only 26% lower risk | The invitation alone helps less, because roughly one in three people never send a sample back. |
| 376,511 people followed for up to 14 years | This is one of the largest real-world screening studies, not a short lab trial. |
| The numbers were adjusted for contamination bias and nonadherence | The team statistically stripped out the “healthy people screen more” effect, so the benefit is more believable. |
| The first step is an at-home stool test | No clinic visit to begin, and only a positive result leads to a colonoscopy. |
Who ran it and how big it was
The study came out of Karolinska Institutet, with the corresponding author Johannes Blom, an associate professor at Sodersjukhuset in Stockholm, working with colleagues Lennarth Nystrom and Hakan Jonsson at Umea University. It was published in JAMA Network Open on 20 August 2026.
The scale is the reason to pay attention. They followed 376,511 people for up to 14 years, and recorded 1,668 deaths from colorectal cancer over that time. That makes it one of the largest looks at a real, population-wide screening program rather than a short trial in a controlled setting.
Everyone in the study was aged 60 to 74, the range Sweden invites for screening every two years.
What the test actually is
There is nothing high-tech about the front end of this. A kit arrives at your home. You provide a small stool sample and post it back. A lab checks it for traces of blood too faint to see. If it finds any, you are offered a colonoscopy to work out why.
Most people who do the test never need that second step. The stool test is the wide net, and the colonoscopy is only for the small share who test positive.
The two numbers, and why they differ
This is where people get tripped up, so it is worth slowing down.
The study reports two separate figures:
- Being invited to screening was tied to a 26% lower risk of dying from colorectal cancer.
- Actually taking part was tied to a 43% lower risk.
Both are real, they just measure different things. The 26% counts everyone who got the invitation, including the roughly one in three who never send a sample back. All those non-participants drag the average benefit down. The 43% isolates the people who actually did the test.
So the practical message is blunt: the invitation sitting unopened on your counter does very little. The test you complete is where the protection lives.
The catch the researchers went after
Here is the honest complication with any “people who get screened live longer” claim. People who show up for health checks tend to be healthier, more organized, and more health-conscious in the first place. That self-selection can make a test look more protective than it really is, because the screened group was already lower-risk before anyone tested anything.
Most screening studies wave at this problem. This one was built around it. The study’s actual title is about outcomes “adjusted for contamination bias and nonadherence,” which is the technical way of saying they tried to statistically remove exactly that distortion. The 43% is the number left standing after that adjustment.
That is a real strength. It is also where the fine print lives. The authors are upfront that these are modeled estimates leaning on statistical corrections, so some uncertainty remains. This is strong, carefully-handled evidence for a benefit. It is not a stopwatch-precise guarantee that the test cuts any one person’s risk by exactly 43%.
As Blom put it, the study “shows that it can actually save lives.” Note the word “can.” Even the lead author keeps it grounded.
Why bowel cancer is worth this trouble
Colorectal cancer is one of the more common cancers worldwide and one of the more survivable when it is caught early. The problem is that early bowel cancer is usually silent. By the time there is visible bleeding, a lasting change in bowel habits, or unexplained weight loss, the disease has often had time to grow.
Screening exists to jump ahead of that. The stool test can flag bleeding long before you would notice it, and a colonoscopy can remove precancerous growths before they ever turn into cancer. Catching it early, or stopping it before it starts, is a completely different fight than treating it once it has spread.
That basic idea, getting ahead of the disease, runs through a lot of cancer care now. In prostate cancer, a focal treatment that targets only the tumor matched surgery on survival with far fewer side effects. Other research pushes further upstream and looks at cutting the risk of ever getting cancer: one large cohort found women on GLP-1 drugs had about 30% lower odds of breast cancer. Screening sits between those two, cheap, early, and aimed squarely at people who feel completely fine.
What to do with this
Fairly simple, actually.
- If a screening kit shows up, use it. That is the single action this whole study points to. An ignored invitation gives you the 26% group’s diluted benefit at best, and really it gives you nothing if you personally never test.
- Know your country’s starting age. Sweden screens 60 to 74. Several programs now begin at 45 or 50, partly because bowel cancer has been climbing in younger adults. Do not assume you are too young to qualify.
- Do not wait for symptoms. Screening is specifically for people who feel fine. Waiting until something feels wrong defeats the entire purpose.
- A positive test is not a diagnosis. Blood in a sample has many harmless causes. It means “let us look closer,” not “you have cancer.” The follow-up colonoscopy is what sorts that out.
The short version: a huge, carefully-adjusted study found that people who did a simple mailed-in stool test had a 43% lower risk of dying from bowel cancer. The test only works if you actually do it. If one lands in your mailbox, that is the whole ballgame.
Sources:
- Karolinska Institutet, “Bowel cancer screening could reduce mortality by over 40 per cent” (https://news.ki.se/bowel-cancer-screening-could-reduce-mortality-by-over-40-per-cent)
- sciencedaily.com, “A simple at-home test could cut colorectal cancer death risk by 43%” (https://www.sciencedaily.com/releases/2026/08/260820202833.htm)
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or screening decision.